Ask AI
ProCE Banner Activity

Treatment Options and Considerations for Newly Diagnosed HER2+ Metastatic Breast Cancer: A Resource for Patients and Caregivers

PDF

Download this brief resource for patients and their caregivers with key information and considerations regarding treatment options for newly diagnosed HER2-positive metastatic breast cancer.

Released: February 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer, Inc.

Target Audience

This activity is intended for oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of maintenance therapy in the first line treatment setting for patients with HER2+ MBC and its impact on the therapeutic index, toxicity, treatment de-escalation, and the burden of treatment for patients

  • Discuss the role of endocrine therapy in the treatment of patients with HER2+/HR+ MBC in the first line setting

Disclosure

Primary Author

Tanya Gupta, MD: advisor: AstraZeneca, Biotheranostics, Gilead, Merck, Novartis, Pfizer.